Literature DB >> 14759719

Metastatic breast cancer response after Exemestane withdrawal: a case report.

S A Bhide1, D W Rea.   

Abstract

A forty-three year old female patient with right sided breast cancer was treated with adjuvant radiotherapy and Tamoxifen. She had a relapse in the right supraclavicular fossa after a disease free period of 12 years. She progressed, after a short period of disease stabilization on Idoxifene followed by a further stable period on Anastrazole. At further disease relapse, she was commenced on Exemestane. After a period of disease stabilization and subsequent disease progression in the right supraclavicular fossa, Exemestane was discontinued. Six weeks later there was a marked regression of the right supraclavicular mass. Withdrawal response to Tamoxifen is well documented. To our knowledge a similar response after Exemestane withdrawal has not been reported in the literature.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14759719     DOI: 10.1016/j.breast.2003.09.009

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  3 in total

1.  Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer.

Authors:  Xiaonan Hou; Fei Huang; Luciana F Macedo; Sean C Harrington; Karen A Reeves; Ann Greer; Friedrich Graf Finckenstein; Angela Brodie; Marco M Gottardis; Joan M Carboni; Paul Haluska
Journal:  Cancer Res       Date:  2011-10-31       Impact factor: 12.701

2.  Endocrine-responsive breast cancer: a 28-year Odyssey.

Authors:  A West; Kp Friedman; F Muggia
Journal:  Ecancermedicalscience       Date:  2011-12-01

3.  Drug withdrawal in women with progressive metastatic breast cancer while on aromatase inhibitor therapy.

Authors:  Y Chavarri-Guerra; M J Higgins; J Szymonifka; T Cigler; P Liedke; A Partridge; J Ligibel; S E Come; D Finkelstein; P D Ryan; P E Goss
Journal:  Br J Cancer       Date:  2014-09-18       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.